Filing Details
- Accession Number:
- 0001638599-16-001038
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2016-06-06 17:34:50
- Reporting Period:
- 2016-06-03
- Filing Date:
- 2016-06-06
- Accepted Time:
- 2016-06-06 17:34:50
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1410098 | Cormedix Inc. | CRMD | Pharmaceutical Preparations (2834) | 000000000 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1535481 | Matthew Duffy | C/O Cormedix Inc. 745 Route 202-206, Suite 303 Bridgewater NJ 08807 | Yes | No | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock, $0.001 Par Value Per Share | Disposition | 2016-06-03 | 46,106 | $2.73 | 28,571 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | S | Direct |
Reported Derivative Holdings
| Sec. Name | Sec. Type | Price | Date | Expiration Date | Amount | Remaning Holdings | Nature of Ownership |
|---|---|---|---|---|---|---|---|
| Common Stock, $0.001 Par Value Per Share | Stock Option (right to buy) | $2.02 | 2024-01-09 | 150,000 | 150,000 | Direct | |
| Common Stock, $0.001 Par Value Per Share | Stock Option (right to buy) | $2.02 | 2024-01-09 | 30,000 | 30,000 | Direct | |
| Common Stock, $0.001 Par Value Per Share | Stock Option (right to buy) | $0.90 | 2023-03-20 | 100,000 | 100,000 | Direct | |
| Common Stock, $0.001 Par Value Per Share | Stock Option (right to buy) | $0.68 | 2022-12-05 | 125,000 | 125,000 | Direct | |
| Common Stock, $0.001 Par Value Per Share | Stock Option (right to buy) | $0.29 | 2022-01-06 | 5,000 | 5,000 | Direct | |
| Common Stock, $0.001 Par Value Per Share | Stock Option (right to buy) | $0.28 | 2021-11-21 | 15,000 | 15,000 | Direct | |
| Common Stock, $0.001 Par Value Per Share | Stock Option (right to buy) | $5.62 | 2025-03-01 | 50,000 | 50,000 | Direct | |
| Common Stock, $0.001 Par Value Per Share | Phantom Stock | $0.00 | 594 | 594 | Direct | ||
| Common Stock, $0.001 Par Value Per Share | Stock Option (right to buy) | $1.91 | 2026-02-21 | 75,000 | 75,000 | Direct | |
| Common Stock, $0.001 Par Value Per Share | Phantom Stock | $0.00 | 1,653 | 1,653 | Direct | ||
| Common Stock, $0.001 Par Value Per Share | Phantom Stock | $0.00 | 1,153 | 1,153 | Direct |
| Expiration Date | Amount | Remaning Holdings | Nature of Ownership |
|---|---|---|---|
| 2024-01-09 | 150,000 | 150,000 | Direct |
| 2024-01-09 | 30,000 | 30,000 | Direct |
| 2023-03-20 | 100,000 | 100,000 | Direct |
| 2022-12-05 | 125,000 | 125,000 | Direct |
| 2022-01-06 | 5,000 | 5,000 | Direct |
| 2021-11-21 | 15,000 | 15,000 | Direct |
| 2025-03-01 | 50,000 | 50,000 | Direct |
| 594 | 594 | Direct | |
| 2026-02-21 | 75,000 | 75,000 | Direct |
| 1,653 | 1,653 | Direct | |
| 1,153 | 1,153 | Direct |
Footnotes
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.67 to $2.77, inclusive.
- These options vested 100% on January 10, 2014.
- These options vest in full on the first anniversary of the date of grant.
- These options vest quarterly over two years.
- These options vest as follows: (a) fifty percent (50%) on the date of issuance of the CE Mark certification for Neutrolin in Europe, which occurred on July 5, 2013, and (b) fifty percent (50%) on December 31, 2013.
- The options vest ratably, one-third of which will vest on each of the grant date, the first anniversary and the second anniversary thereof.
- Each share of phantom stock is the economic equivalent of one share of common stock. The shares of phantom stock become payable in common stock on the tenth business day of January of the year following the reporting person's termination of service as a directo
Billionaire Hedge Funds
